REG - Inspiration Health - Appointment of Nominated Adviser and Broker

Inspiration HealthcareAnnouncement

24/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230524:nRSX3998Aa&default-theme=true

RNS Number : 3998A  Inspiration Healthcare Group PLC  24 May 2023

24 May 2023

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

Appointment of Nominated Adviser and Broker

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company pioneering best-in class, specialist neonatal intensive care medical
devices, announces the appointment of Liberum Capital Limited ("Liberum") as
the Company's Nominated Adviser and sole Broker with immediate effect.

 

 Inspiration Healthcare Group plc                                                   Tel: +44  (0)330 175 0000

 Neil Campbell, Chief Executive Officer
 Paul Bergin, Interim Chief Financial Officer

 Liberum (Nominated Adviser & Broker)                                                                              Tel: +44 (0)20
                                                                                    3100 2000
 Phil Walker, Richard Lindley, William Hall, Will King

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
 Anna Dunphy                                                                        Mob: +44 (0) 7876 741 001
 Stephanie Cuthbert                                                                 Mob: +44 (0) 7796 794 663
 Louis Ashe-Jepson                                                                  Mob: +44 (0) 7747 515 393

 

 

About Inspiration Healthcare Group plc

 

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology
for use in neonatal intensive care & operating theatres. The Company
provides high quality innovative products to patients around the world which
help to improve patient outcomes and it actively invests in innovative product
opportunities and disruptive technologies.

 

The Company has key own brand products that can be used within the first days
of life to help premature and sick babies; helping resuscitation and
stabilisation in the first moments of life through to preventing brain damage
and both invasive and non-invasive respiratory support in terms of capital
equipment and disposable medical devices. Additionally, the Company has its
own range of products for maintaining normothermia pre, during and
post-surgery.

 

Since September 2019, the Company has acquired Vio Holdings a designer,
manufacturer and supplier of single use respiratory products and sterile
medical consumables and S.L.E., a leading designer, manufacturer and global
provider of neonatal ventilation products.  The Group generates approximately
58% of its revenues from export markets and more than half of its revenues
come from its own-branded products.

 

With product availability actively promoted to over 80 countries through a
distribution network, Inspiration Healthcare's success has been built on
continuous innovation, excellent customer service and an inherent commitment
to improving patient outcomes, working in close collaboration with key opinion
leaders across the globe.

 

In the UK and Ireland, the Group has direct sales teams selling Group Branded
and complementary products from third parties, with an additional range of
home healthcare products.  This is supported by Technical Support for planned
preventative maintenance and emergency assistance.

The Group operates from various sites in the UK for R&D, Marketing and
operations with manufacturing based in Croydon (south London) and Hailsham
(East Sussex).  The Group's Head Office is located in Crawley, a short
distance from London's Gatwick Airport.

 

Further information on Inspiration Healthcare can be found at
www.inspirationhealthcaregroup.com (http://www.inspirationhealthcaregroup.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPUOOVROAUVUAR